Immunovant Reports Q4 GAAP EPS of -$0.73, Misses Estimates
Immunovant (IMVT) reported a fourth-quarter GAAP earnings per share loss of $0.73, missing estimates by $0.13. The company also announced cash and equivalents totaling approximately $902.1 million as of March 31, 2026.
Tickers: $IMVT
Topics: cash_position financial_results